Poly Medicure Limited has scheduled one-on-one investor meetings on June 12, 2026, with Carnelian Asset Management and Quant Mutual Fund. The interactions will take place at the company's plant located in the HSIIDC Industrial Area, Sector-59, Faridabad. These meetings are aimed at engaging with analysts and investors to discuss business operations and strategy.

The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that no unpublished price sensitive information will be shared during these sessions. The intimation was submitted on a shorter notice due to the confirmation of the schedule being received late.

Scheduled Investor Meetings

The following table details the upcoming engagements:

Poly Medicure Limited has appointed Mr. Indranil Mukherjee as Chief Executive Officer - Asia Pacific and India Business effective June 1, 2026. The appointment, approved by the Board of Directors via circular resolutions based on the recommendation of the Nomination and Remuneration Committee, strengthens the company's leadership team. Mr. Mukherjee will report directly to the Managing Director and has been categorized as Senior Management Personnel (SMP) under the SEBI Listing Regulations.

Mr. Indranil Mukherjee is a seasoned medical technology executive with over 30 years of broad-based leadership experience. His expertise spans critical care, infusion therapy, renal care, surgical instruments, vascular systems, wound care, and implantable devices. He has a demonstrated track record of acting as a change agent, scaling up business, leading market expansion, managing M&A and integration, and executing strategy.

He built the foundational years of his career at B. Braun, managing the Hospital Care, Outpatient Market, and Aesculap (Vascular) portfolios across India. He later transferred to B. Braun's headquarters in Germany as Global Sales Manager in 2010 and subsequently served as Regional Head for Hospital Care at the Asia Pacific headquarters in Penang, Malaysia. As Managing Director at B. Braun Group in India, he delivered a turnaround and sustained profitable growth across multiple product lines spanning three manufacturing plants and a team of over 2,000 colleagues.

Most recently, Mr. Mukherjee served as Group Chief Executive Officer of Translumina Therapeutics, a global cardiovascular implants company with operations in India and Germany. His career reflects deep expertise across the full spectrum of medical devices, from consumables to capital equipment and implants, combined with a proven track record of building high-performance commercial organisations and driving P&L responsibilities at country, regional, and global levels. He graduated in Chemistry from St. Xavier's College Ranchi and holds an MBA from Bhopal University, followed by SMP from IIM Calcutta and LBTA from INSEAD Singapore.

Key Appointment Details